Pipeline

Development Stage and Anticipated Milestones TherapeuticIndication AntibodyProgram IND Enabling Phase 1 Phase 2 Phase 3 Rosnilimab(Pathogenic T cell depleter) P2 data throughWeek 12 Q4 2025 ANB033(CD122 antagonist) Celiac Disease Ulcerative Colitis Rheumatoid Arthritis P1b to initiate by Q4 2025R&D event in Q4 2025 P1b to initiatein 2026 Inflammatory Disease Trial completeFinal data to be presented ata future medical conference Immune Cell Modulators P1 in healthyvolunteers ongoing ANB101(BDCA2 modulator) Inflammatory Disease